Travere Therapeutics, INC Form 4 insider transactions

Travere Therapeutics' Chief Medical Officer, Jula Inrig, exercised stock options and subsequently sold 15,000 shares of common stock.

Travere Therapeutics' SVP, Chief Accounting Officer Sandra Calvin sold 7,402 shares of common stock for $40 per share, reducing her direct beneficial ownership to 38,233 shares.

Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, sold 2,910 shares of common stock for $36 per share under a pre-arranged trading plan.

Travere Therapeutics' CFO, Christopher R. Cline, exercised stock options and sold 20,000 shares of common stock under a pre-arranged 10b5-1 plan.

Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, sold 67,115 shares of common stock at $36.00 after exercising various stock options.

Travere Therapeutics Director Timothy Coughlin exercised stock options and subsequently sold 18,000 shares of common stock for a profit.

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, reported the sale of 5,591 shares and a charitable gift of 1,078 shares of common stock.

Travere Therapeutics CEO Eric Dube exercised stock options and subsequently sold 129,999 shares of common stock in late October 2025 under a pre-arranged trading plan.

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, Inc., sold 2,662 shares of common stock at $30 per share pursuant to a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, made a charitable gift of 891 shares of common stock under a pre-arranged 10b5-1 plan.

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, exercised stock options and subsequently sold 10,000 shares under a pre-arranged 10b5-1 plan.

Travere Therapeutics CFO Christopher R. Cline reported the sale of 573 common shares in two transactions to cover tax withholding obligations and pursuant to a pre-arranged trading plan.

Travere Therapeutics CFO Christopher R. Cline sold 470 shares of common stock for $17.31 per share, as part of a pre-arranged 10b5-1 plan to cover tax obligations.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold 815 shares of common stock at $14.65 per share on July 1, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Director Brinkley Ruth Williams reports acquisition of 6,500 shares and disposal of 25,750 shares of Travere Therapeutics common stock on May 15, 2025, along with stock option grants.

Director Ron Squarer reports acquisition of 6,500 shares of common stock and 19,500 stock options, along with the disposal of 6,500 shares.

Director Sandra Poole reports acquiring shares and disposing of shares of Travere Therapeutics, Inc. common stock on May 15, 2025.

Director John A. Orwin acquired 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc. on May 15, 2025, according to a Form 4 filing.

Jeffrey A. Meckler, a director at Travere Therapeutics, received an automatic equity grant and disposed of shares on May 15, 2025.

Gary A. Lyons, a director of Travere Therapeutics, reports acquiring and disposing of common stock and stock options on May 15, 2025, according to a Form 4 filing.

Director Timothy Coughlin reports acquisition of 6,500 shares and disposal of shares of Travere Therapeutics, Inc. on May 15, 2025.

Director Suzanne Bruhn acquired 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics on May 15, 2025, under the company's equity incentive plan.

Roy D. Baynes, a director of Travere Therapeutics, reported the acquisition of 6,500 shares of common stock and 19,500 stock options on May 15, 2025, according to a Form 4 filing with the SEC.

Christopher R. Cline, CFO of Travere Therapeutics, reports the vesting of performance-based restricted stock units (PSUs) and subsequent sale of shares to cover tax obligations.

Travere Therapeutics CEO Eric Dube exercised performance-based restricted stock units (PSUs) and sold a portion of the acquired shares to cover tax obligations.

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, reports the vesting of performance-based restricted stock units and subsequent sale of shares to cover tax obligations.

William E. Rote, Chief Research Officer at Travere Therapeutics, reports the vesting of performance-based restricted stock units and subsequent sale of shares.

Elizabeth E. Reed, Chief Legal Officer and GC of Travere Therapeutics, exercised performance-based restricted stock units and sold shares to cover tax obligations following the achievement of a revenue-related performance criterion.

Christopher R. Cline, CFO of Travere Therapeutics, sold shares to cover tax withholding obligations related to vested restricted stock units.

William E. Rote, Senior Vice President of R&D at Travere Therapeutics, exercised performance-based restricted stock units (PSUs) and sold a portion of the acquired shares to cover tax obligations after the company confirmed a path forward for traditional approval of FILSPARI.